Evolving Treatments for Primary Central Nervous System Lymphoma

Area of Science:

• Neuro-oncology
• Hematologic malignancies
• Lymphoma research

Background:

• Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the CNS.
• Over 95% of PCNSL cases exhibit diffuse large B-cell lymphoma (DLBCL) morphology.
• PCNSL was historically considered incurable, but recent therapeutic advances show progress.

Purpose of the Study:

• To review the current understanding and evolving treatment landscape of PCNSL.
• To highlight the need for efficient diagnosis, staging, and experienced care centers.
• To discuss challenges and future directions in PCNSL management, including precision medicine.

Main Methods:

• Review of current literature and clinical research on PCNSL.
• Analysis of established and emerging therapeutic strategies.
• Consideration of patient-specific factors, including age and treatment tolerance.

Main Results:

• High-dose methotrexate (MTX) and rituximab are key components of current induction regimens.
• Challenges include developing less toxic regimens and effective consolidation for elderly patients.
• Maintenance therapy, immunotherapy, and targeted agents offer new avenues for precision medicine.

Conclusions:

• PCNSL treatment is rapidly evolving, moving towards more personalized approaches.
• Optimizing induction and consolidation strategies is crucial, especially for older adults.
• Precision medicine holds promise for achieving long-term survival and cure with reduced neurotoxicity.